Figure 8.

Schematic of bioengineered cell membrane nanovesicle coated oncolytic adenoviruses (OA@BCMNs) for OA delivery and in vivo antitumor efficacy of OA@BCMNs. (A) Design features and proposed mechanism of OA@BCMNs. The BCMNs encapsulated OA, protecting OAs from neutralizing antibodies and delivering them to tumors through receptor mediated endocytosis. Once entered tumor cells, OAs infect and amplify the tumor cells, causing the tumor cell lysis. (B) Viral genome copies in excised tumors and organs, after intravenous injection of OA and OA@BCMNs-preS1 into HepG2-NTCP bearing nude mouse model, were quantified using real time qPCR. (C) Tumor growth curve of HepG2-NTCP bearing nude mouse model after the indicated treatment. (D) Tumor growth curve of HepG2-APN bearing mouse model after the indicated treatment. Reproduced with permission from ref 113. Copyright 2019 American Chemical Society.